Institute of Clinical Physiology, National Research Council, Pisa, Italy.
Clin Endocrinol (Oxf). 2014 Apr;80(4):545-53. doi: 10.1111/cen.12199. Epub 2013 Apr 11.
To determine the effect of chronic daily exenatide treatment on β-cell function in type 2 diabetes (T2DM).
Glucagon-like peptide receptor agonists, such as exenatide, are commonly used to treat patients with T2DM. Drugs in this class are insulinotropic but lower blood glucose by multiple mechanisms such that effects on β-cell function can be difficult to discern by conventional measures.
Seventy-nine subjects with previously untreated T2DM were studied before and after 24 weeks of treatment with one of the two doses of exenatide, 5- or 10-μg twice daily, or placebo. All subjects had oral glucose tolerance tests (OGTT) before and after randomization with measurement of plasma glucose, insulin and C-peptide concentrations. Insulin secretion rates (ISR), peripheral insulin sensitivity (OGIS) and hepatic insulin resistance index (Hep-IR) were calculated.
During the trial, all three groups lost similar, small but significant, amounts of weight. Compared to placebo, 24 weeks of daily high- or low-dose exenatide treatment reduced HbA1c and improved fasting and postprandial hyperglycaemia. Exenatide was associated with improved OGIS and Hep-IR independent of changes in weight. Plasma insulin levels and ISR during the OGTT did not differ before or after treatment with exenatide or placebo. However, when considered as a function of plasma glucose and insulin sensitivity, both doses of exenatide improved ISR proportionately to the improvement in plasma glucose. The higher dose of exenatide was associated with a significant improvement in β-cell sensitivity to glucose.
These findings demonstrate that in persons with early T2DM, chronic treatment with exenatide enhanced ISR and increased β-cell sensitivity to glucose. These improvements in β-cell function were not clearly reflected in plasma insulin and C-peptide levels, but became apparent when glycemia and insulin sensitivity were accounted for.
确定慢性每日 exenatide 治疗对 2 型糖尿病(T2DM)患者β细胞功能的影响。
胰高血糖素样肽受体激动剂,如 exenatide,常用于治疗 T2DM 患者。该类药物具有胰岛素促泌作用,但通过多种机制降低血糖,因此通过常规方法很难确定对β细胞功能的影响。
79 例未经治疗的 T2DM 患者在接受 5μg 或 10μg 每日两次或安慰剂治疗 24 周前后进行研究。所有患者在随机分组前后均进行口服葡萄糖耐量试验(OGTT),并测量血浆葡萄糖、胰岛素和 C 肽浓度。计算胰岛素分泌率(ISR)、外周胰岛素敏感性(OGIS)和肝胰岛素抵抗指数(Hep-IR)。
在试验期间,所有三组体重均减轻,且减轻量相似,但均具有统计学意义。与安慰剂相比,24 周的每日高剂量或低剂量 exenatide 治疗可降低 HbA1c,并改善空腹和餐后高血糖。Exenatide 与改善 OGIS 和 Hep-IR 相关,而与体重变化无关。OGTT 前后的血浆胰岛素水平和 ISR 在 exenatide 或安慰剂治疗前后无差异。然而,当将其作为血浆葡萄糖和胰岛素敏感性的函数考虑时,两种剂量的 exenatide 均使 ISR 与血浆葡萄糖的改善成比例地改善。高剂量的 exenatide 与β细胞对葡萄糖的敏感性显著改善有关。
这些发现表明,在早期 T2DM 患者中,慢性 exenatide 治疗可增强 ISR 并提高β细胞对葡萄糖的敏感性。这些β细胞功能的改善在血浆胰岛素和 C 肽水平上没有明显反映,但当考虑血糖和胰岛素敏感性时,这些改善变得明显。